The liquid biopsy series: A cytopathological perspective

Affiliations

¹ Department of Public Health, University of Naples Federico II, Naples, Italy.
² Department of Pathology, Medipath and the American Hospital of Paris, Paris, France.

Editorial

Pasquale Pisapia et al. Cytopathology. 2023 Nov.

. 2023 Nov;34(6):517-518.

doi: 10.1111/cyt.13302. Epub 2023 Sep 7.

¹ Department of Public Health, University of Naples Federico II, Naples, Italy.
² Department of Pathology, Medipath and the American Hospital of Paris, Paris, France.

No abstract available

References

1. Gambardella V, Tarazona N, Cejalvo JM, et al. Personalized medicine: recent progress in cancer therapy. Cancers. 2020;12:1009.
1. Wästerlid T, Cavelier L, Haferlach C, et al. Application of precision medicine in clinical routine in haematology-challenges and opportunities. J Intern Med. 2022;292:243-261.
1. Malapelle U, Tiseo M, Vivancos A, Kapp J, Serrano MJ, Tiemann M. Liquid biopsy for biomarker testing in non-small cell lung cancer: a European perspective. J Mol Pathol. 2021;2:255-273.
1. Hirsch FR, Wynes MW, Gandara DR, Bunn PA Jr. The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res. 2010;16:4909-4911.
1. Krebs MG, Malapelle U, André F, et al. Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: a narrative review. JAMA Oncol. 2022;8:1830-1839.